Omeza Appoints New Director of Sales – East Region

Jim McSweeney an accomplished sales professional in chronic wound care space

Director of Sales – East

SARASOTA, Fla. Oct. 13,2021 – Omeza, LLC announced that James “Jim” McSweeney is joining the company in the role of Director of Sales – East Region effective October 11, 2021. Mr. McSweeney has worked for 3M/KCI since 2018 and currently holds the position of Director Corporate Accounts.

In his new role, Mr. McSweeney will be central to Omeza’s strategy of wound healing delivered simply and completely to restore patient quality of life. Omeza recently received 510(k) approval of its lead drug-device combination product, Omeza® Collagen Matrix, and FDA clearance to go to market.

Company Founder and CEO Tom Gardner, commented, “Jim brings significant expertise into this new, critical role for our organization. His extensive experience in chronic wound care, ability to drive sales organizations, and depth of knowledge about customer requirements will be valuable in the commercial launch of our lead Rx only Omeza® Collagen Matrix as well as our 2 OTC drugs, Omeza® Lidocaine Lavage and Omeza® Skin Protectant.  I am confident that Jim will be successful in helping to drive our growth.”

Mr. McSweeney began his career at Novartis, progressing to Senior Account Specialist in the Specialty Tissue Engineering Division — which was sold to Organogenesis in 2003. He became Regional Sales Manager for Organogenesis, building sales for their Apligraf® Tissue Substitute product before leaving to join advanced wound care startup Spiracur, Inc. in 2012 as Regional Sales Manager Northeast to help launch Spiracur’s novel Negative Pressure Wound Treatment called SNAP®. Spiracur was acquired by KCI in 2015, and KCI was acquired by 3M in 2019.

Mr. McSweeney commented, “I am excited to help drive the growth of Omeza and look forward to bringing the technology to underserved markets.”